Abstract:Weily Soong, 1 Bradley E Chipps, 2 Warner Carr, 3 Jennifer Trevor, 4 Arpan Patel, 5 Nicole Clarke, 6 Donna D Carstens, 5 Christopher S Ambrose 6 1 AllerVie Health, AllerVie Clinical Research, Birmingham, AL, USA; 2 Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA; 3 Allergy & Asthma Associates of Southern California, Food Allergy Center of Southern California, Mission Viejo, CA, USA; 4 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 5 BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 6 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA Correspondence: Christopher S Ambrose, BioPharmaceuticals Medical, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA, Tel +1 301-398-4454, Email Purpose: Patients living with severe asthma (SA) experience multiple health-related quality of life (HRQoL) impairments. This study examined HRQoL changes after biologic treatment initiation among a large, real-world cohort of patients with SA. Patients and methods: CHRONICLE is an ongoing observational study of subspecialist-treated adults with SA who receive biologics or maintenance systemic corticosteroids or are uncontrolled on high-dosage inhaled corticosteroids with additional controllers. Patients enrolled February 2018–February 2023 were asked to complete the St. George's Respiratory Questionnaire (SGRQ) every 6 months (total score range of 0– 100 [0=best possible health], meaningful change threshold is a 4-unit reduction in the total score). Changes in SGRQ responses from 6 months before initiation to 12 to 18 months after initiation were summarized. Results: A total of 76 patients completed the SGRQ 0 to 6 months before and 12 to 18 months after biologic initiation. The mean (SD) SGRQ total score decreased from 52.2 (20.6) to 41.9 (23.8), with improvement across the symptoms (− 14.5), activity (− 11.0), and impacts (− 8.3) components. For specific impairments reported by ≥ 50% of patients before biologic initiation, fewer reported each impairment after biologic initiation; the largest reductions were for "Questions about what activities usually make you feel short of breath these days [Walking outside on level ground]" (67% to 43%), "Questions about other effects that your respiratory problems may have on you these days [I feel that I am not in control of my respiratory problems]" (55% to 34%), and "Questions about your cough and shortness of breath these days [My coughing or breathing disturbs my sleep]" (63% to 45%). Conclusion: In this real-world cohort of adults with SA, biologic initiation was associated with meaningful improvements in asthma-related HRQoL. These data provide further insight into the burden SA places on patients and the benefits of biologic treatment. Keywords: observational, real-world, health-related quality of life, St. George's Respiratory Questionnaire An estimated 5% to 10% of individuals with asthma have severe asthma (SA), which is defined by the requirement for high-dosage inhaled corticosteroids and additional controllers. 1,2 As compared with the general asthma patient population, patients with SA experience a disproportionately greater burden of symptoms, exacerbations, and treatment requirements, with a commensurate impact on health-related quality of life (HRQoL). 3,4 Patients with persistently uncontrolled SA despite the use of high-dosage inhaled corticosteroids and additional controllers are potential candidates for biologic treatments, which have been shown to reduce asthma exacerbations and the need for oral corticosteroids (OCS) as well as to improve lung function, symptoms, and HRQoL, although specific demonstrated effects vary across biologics. 5 In their treatment preferences and goals, patients with SA may prioritize HRQoL improvements above other outcomes, including the number and severity of exacerbations. 6 Clinical trials and a small number of real-world studies in SA have shown improvements in HRQoL associated with biologic use. 7–15 However, the few real-world studies conducted in the US were treatment-specific and varied in design, patient population, and assessment instruments. 14,15 The impact of biologic treatments as a class on HRQoL in patients with SA in longer-term real-world settings has not been well described. Thus, the objective of this analysis was to examine changes in HRQoL after approximately 1 year of biologic treatment in a broad, real-world sample of US patients with SA. CHRONICLE (ClinicalTrials.gov: NCT03373045) is an ongoing real-world obser -Abstract Truncated-

Severe asthma biologics use in England: a need to increase use and reduce inequity

Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK

Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry

Optimizing severe asthma care by consulting an asthma expertise team for biologics

Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study

Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma

Real-world biologics response and super-response in the International Severe Asthma Registry cohort

Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma

How I do it. Choosing the right biologic for the right patient with severe asthma

Future of biologics in pediatric asthma: Optimizing response, early introduction, and equitable access to treatment

Biologics in T2 Severe Asthma: Unveiling Different Effectiveness by Real-World Indirect Comparison

Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma

Stepping down biologics in asthma: is it time to challenge the status quo?

Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Overuse of Oral Corticosteroids, Underuse of Inhaled Corticosteroids, and Implications for Biologic Therapy in Asthma

Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR

The emergence of new biologics for severe asthma

Bronchiectasis in severe asthma: clinical and inflammatory response to biologic therapy.

Biologics for the treatment of severe asthma: Current status report 2023